rs948589

Variant summary

Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1

The NM_005359.6(SMAD4):​c.905-52A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0697 in 1,374,694 control chromosomes in the GnomAD database, including 3,902 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.052 ( 253 hom., cov: 32)
Exomes 𝑓: 0.072 ( 3649 hom. )

Consequence

SMAD4
NM_005359.6 intron

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: 1.68

Publications

4 publications found
Variant links:
Genes affected
SMAD4 (HGNC:6770): (SMAD family member 4) This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasing blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, May 2022]
SMAD4 Gene-Disease associations (from GenCC):
  • juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Genomics England PanelApp, G2P, PanelApp Australia
  • Myhre syndrome
    Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Orphanet, G2P, Labcorp Genetics (formerly Invitae)
  • generalized juvenile polyposis/juvenile polyposis coli
    Inheritance: AD Classification: STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp
  • juvenile polyposis syndrome
    Inheritance: AD Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • familial thoracic aortic aneurysm and aortic dissection
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary hemorrhagic telangiectasia
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • pulmonary arterial hypertension
    Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -20 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.85).
BP6
Variant 18-51059814-A-G is Benign according to our data. Variant chr18-51059814-A-G is described in ClinVar as Benign. ClinVar VariationId is 24817.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.0793 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
SMAD4NM_005359.6 linkc.905-52A>G intron_variant Intron 7 of 11 ENST00000342988.8 NP_005350.1 Q13485A0A024R274

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
SMAD4ENST00000342988.8 linkc.905-52A>G intron_variant Intron 7 of 11 5 NM_005359.6 ENSP00000341551.3 Q13485

Frequencies

GnomAD3 genomes
AF:
0.0525
AC:
7989
AN:
152192
Hom.:
253
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0142
Gnomad AMI
AF:
0.0835
Gnomad AMR
AF:
0.0276
Gnomad ASJ
AF:
0.0476
Gnomad EAS
AF:
0.00115
Gnomad SAS
AF:
0.0484
Gnomad FIN
AF:
0.0850
Gnomad MID
AF:
0.0316
Gnomad NFE
AF:
0.0811
Gnomad OTH
AF:
0.0325
GnomAD4 exome
AF:
0.0718
AC:
87827
AN:
1222384
Hom.:
3649
Cov.:
17
AF XY:
0.0710
AC XY:
44022
AN XY:
619904
show subpopulations
African (AFR)
AF:
0.0104
AC:
300
AN:
28750
American (AMR)
AF:
0.0194
AC:
860
AN:
44318
Ashkenazi Jewish (ASJ)
AF:
0.0567
AC:
1393
AN:
24556
East Asian (EAS)
AF:
0.00112
AC:
43
AN:
38530
South Asian (SAS)
AF:
0.0428
AC:
3471
AN:
81130
European-Finnish (FIN)
AF:
0.0863
AC:
4579
AN:
53032
Middle Eastern (MID)
AF:
0.0275
AC:
147
AN:
5340
European-Non Finnish (NFE)
AF:
0.0823
AC:
73637
AN:
894272
Other (OTH)
AF:
0.0648
AC:
3397
AN:
52456
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
4140
8280
12420
16560
20700
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2356
4712
7068
9424
11780
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0524
AC:
7987
AN:
152310
Hom.:
253
Cov.:
32
AF XY:
0.0512
AC XY:
3817
AN XY:
74480
show subpopulations
African (AFR)
AF:
0.0142
AC:
590
AN:
41582
American (AMR)
AF:
0.0275
AC:
421
AN:
15298
Ashkenazi Jewish (ASJ)
AF:
0.0476
AC:
165
AN:
3470
East Asian (EAS)
AF:
0.00116
AC:
6
AN:
5192
South Asian (SAS)
AF:
0.0484
AC:
234
AN:
4832
European-Finnish (FIN)
AF:
0.0850
AC:
902
AN:
10614
Middle Eastern (MID)
AF:
0.0272
AC:
8
AN:
294
European-Non Finnish (NFE)
AF:
0.0811
AC:
5517
AN:
68004
Other (OTH)
AF:
0.0322
AC:
68
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
401
803
1204
1606
2007
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
94
188
282
376
470
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0508
Hom.:
95
Bravo
AF:
0.0462
Asia WGS
AF:
0.0170
AC:
58
AN:
3476

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Mar 03, 2015
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

not specified Benign:1
Jul 03, 2018
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Myhre syndrome Benign:1
Feb 01, 2025
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Juvenile polyposis syndrome Benign:1
Jul 07, 2023
KCCC/NGS Laboratory, Kuwait Cancer Control Center
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.85
CADD
Benign
8.3
DANN
Benign
0.74
PhyloP100
1.7
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs948589; hg19: chr18-48586184; COSMIC: COSV61694707; API